Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryDec082021	Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting SAN DIEGO , Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event entitled “B -cell Read All »	View HTML
Toggle SummaryNov112021	Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company Read All »	View HTML
Toggle SummaryNov092021	Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today Read All »	View HTML
Toggle SummaryNov042021	Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 for R/R Lymphoma Showed 71% ORR and 50% CR; Differentiated Safety Profile with Two Low-Grade Events of CRS and No Events Read All »	View HTML
Toggle SummaryNov042021	Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13 Company to Host Virtual Investor Event on Tuesday, December 14 SAN DIEGO , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML
Toggle SummaryOct252021	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results SAN DIEGO , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a Read All »	View HTML
Toggle SummaryOct012021	Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting SAN DIEGO , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Read All »	View HTML
Toggle SummarySep152021	Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK Cells SAN DIEGO , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the Read All »	View HTML
Toggle SummarySep022021	Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor Read All »	View HTML
Toggle SummaryAug192021	Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma 10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rituximab Following Autologous CD19 CAR T-cell Therapy 8 of 11 Patients in FT516 Multi-Dose Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.